Paratek to Receive $4 Million Payment From Actavis With Initiation of Phase 3 Trial of Sarecycline
January 06, 2015 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced Actavis will be making a $4 million milestone payment to Paratek under the terms of the parties'...
Paratek Pharmaceuticals Announces Appointment of Douglas Pagan as Chief Financial Officer
December 03, 2014 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced Douglas Pagán will join Paratek's executive leadership team as chief financial officer,...
Paratek Pharmaceuticals Highlights Newly Expanded Board of Directors
November 06, 2014 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) recently announced the members of its newly expanded board of directors. Michael F Bigham, Thomas J. Dietz, Ph.D,...
Paratek Pharmaceuticals Strengthens Management Team
November 04, 2014 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 4, 2014 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced the addition of three new, experienced individuals to its management team. They bring significant...
Paratek Pharmaceuticals Completes Merger With Transcept Pharmaceuticals
October 30, 2014 13:31 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) and Transcept Pharmaceuticals, Inc. (Nasdaq:TSPT) (through October 30) today announced the two companies have...
Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO
July 01, 2014 06:30 ET
|
Paratek Pharmaceuticals
BOSTON, July 1, 2014 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., today announced that Michael F. Bigham, Partner at Abingworth LLP, has been appointed as Chairman of the Board of Directors and...